LUCENTIS is a prescription medicine that is designed to block vascular endothelial (VASS‐cue‐ler end‐oh‐THEEL‐e‐ull) growth factor, or VEGF (vej‐EFF), from inside the eye. It was approved in 2010 to treat macular edema caused by retinal vein occlusion (RVO).
The eye contains a protein called vascular endothelial growth factor, or VEGF. The role of VEGF is to help grow new blood vessels.
Macular edema following retinal vein occlusion (RVO) is caused by an excess of VEGF in addition to vessel blockages. This leads to the abnormal blood vessel growth that can cause vision problems
The vision problems a retinal vein occlusion patient may experience will depend on which retinal vein blockage a patient is suffering from
Your doctor can detect changes or problems in your vision with a visual acuity test. Visual acuity tests find the smallest letters you can see on a standard eye chart. Visual acuity is the sharpness of your vision.
Visual acuity is expressed as a fraction such as 20/40 or a single number such as 1.5.
The effects of RVO may improve with treatment, but some damage may be permanent.
There may be options to help you afford LUCENTIS, no matter what type of health insurance you have. Learn about Genentech Ophthalmology Access Solutions.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.